Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases

Current treatment strategies of autoimmune diseases (ADs) display a limited efficacy and cause numerous adverse effects. Phosphodiesterase (PDE)4 and PDE7 inhibitors have been studied recently as a potential treatment of a variety of ADs. In this study, a PK/PD disease progression modeling approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Świerczek, Artur, Pociecha, Krzysztof, Plutecka, Hanna, Ślusarczyk, Marietta, Chłoń-Rzepa, Grażyna, Wyska, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147171/
https://www.ncbi.nlm.nih.gov/pubmed/35631676
http://dx.doi.org/10.3390/pharmaceutics14051090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147171/
https://www.ncbi.nlm.nih.gov/pubmed/35631676
http://dx.doi.org/10.3390/pharmaceutics14051090

Ejemplares similares